Cat. No.: DAB-0011838
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgM |
| Host Species | Mouse |
| Reactivity | Human |
| Applications | IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with B3GAT1 expressing human peripheral blood mononuclear cells. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | B3GAT1 |
| UniProt No. | Q9P2W7 |
| Gene ID | 27087 |
| Gene Description | Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1, also known as beta-1, 3-glucuronyltransferase 1 and glucuronosyltransferase P, is a type II membrane protein enzyme encoded by the B3GAT1 gene. This gene is localized on the 11q25 chromosome and is a member of the glucuronyltransferase gene family. B3GAT1 is one of the enzymes involved in the biosynthesis of carbohydrate epitope human natural killer-1, also known as CD57 and Leu7. B3GAT1 catalyzes the glucuronyl transfer reaction that adds a glucuronic acid to the terminal N-acetyllactosamine disaccharide to form the CD57 epitope on a variety of proteins, lipids, and chondroitin sulfate proteoglycans at the cell surface. CD57 is present on a subset of peripheral blood lymphocytes, including NK cells and CD8+ T cells, as well as neural cells and striated muscle. The CD57 epitope may play a role in neural cell adhesion, and characterizes unique maturation states in T and NK cells. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Stored at 4 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in a PBS-based buffer with ~1% BSA and less than 0.1% sodium azide. Stable for 6 months when |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
